Table 2. Post-treatment malaria transmission in relation to mutations in the dhfr and dhps genes.

	Double mutation *	≥ three mutations *	p-value
Median gametocyte density/µL ¥ on day of feeding, (IQR)
Non-ACT	10.40 (3.83–30.33)	4.96 (0.51–22.47)	0.27
ACT	0.84 (0.03–1.94)	0.17 (0.04–1.01)	0.66
Proportion of children infecting at least one mosquito, % (n/N)
Non-ACT	77.8 (7/9)	73.5 (25/34)	1.00
ACT	50.0 (3/6)	62.5 (5/8)	1.00
Proportion of infected mosquitoes, % (n/N)§
Non-ACT	7.0 (19/270)	6.0 (61/1020)	0.79
ACT	3.2 (6/180)	3.3 (8/240)	0.65

IQR = interquartile range; Non-ACT = treatment with sulphadoxine-pyrimethamine (SP) alone or in combination with amodiaquine; ACT = treatment with SP and artesunate (3 days).

^¥Gametocyte densities were measured by Pfs25 QT-NASBA.

^*Mutations were determined at enrolment: double mutation = mutations in c108+c59 or c108+c51; ≥ three mutations = mutations in c51+c59+c108 and possible additional mutations;

^§estimates were adjusted for correlation between observations from the same individual.